References
- Squires JE, Balistreri WF. Hepatitis C virus infection in children and adolescents. Hepatol Commun. 2017 [cited 2017 Mar 23];1(2):87–98. doi: 10.1002/hep4.1028
- Hepatitis C. World Health Organization. Jun 2022. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
- Prescribing Information for Epclusa. Gilead. 2022. https://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf
- Ahmed R, Kareem R, Venkatesan N, et al. Sofosbuvir/Velpatasvir - a promising treatment for chronic hepatitis C virus infection. Cureus. 2021 [cited 2021 Aug 16];13(8):e17237. doi: 10.7759/cureus.17237
- Rogers ME, Balistreri WF. Cascade of care for children and adolescents with chronic hepatitis C. World J Gastroenterol. 2021;27(12):1117–1131. doi: 10.3748/wjg.v27.i12.1117
- HCV guidance: recommendations for testing, managing, and treating hepatitis C. AASLD/IDSA. Oct 2022. https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/AASLD-IDSA_HCVGuidance_October_24_2022.pdf
- Epclusa assessment report. European Medicines Agency. 26 May 2016. https://www.ema.europa.eu/en/documents/assessment-report/epclusa-epar-public-assessment-report_en.pdf
- Summary on compassionate use for Ledipasvir/Sofosbuvir. European Medicines Agency, 2014. https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-ledipasvir/sofosbuvir_en.pdf
- Smolders EJ, Jansen AME, Ter Horst PGJ, et al. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations: a 2019 update. Clin Pharmacokinet. 2019;58(10):1237–1263. doi: 10.1007/s40262-019-00774-0
- Kirby B, Gordi T, Symonds W, et al. Population pharmacokinetics of sofosbuvir and its major metabolite (GS-331007) in healthy and HCV-Infected adult subjects. AASLD. 2013. https://www.natap.org/2013/AASLD/AASLD_69.htm
- Loucks CM, Lin JJ, Trueman JN, et al. Patient-specific genetic factors predict treatment failure in sofosbuvir-treated patients with chronic hepatitis C. Liver Int. 2022;42(4):796–808. doi: 10.1111/liv.15175
- Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015;373(27):2599–2607. doi: 10.1056/NEJMoa1512610
- Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608–2617. doi: 10.1056/NEJMoa1512612
- Wyles D, Bräu N, Kottilil S, et al. Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase 3 study. Clinl Infect Dis. 2017;65(1):6–12.
- Sofosbuvir-Velpatasvir. Hepatitis C online. 2023. https://www.hepatitisc.uw.edu/page/treatment/drugs/epclusa/prescribing-information#S14.8
- U.S. FDA Approves Expanded Labeling For Epclusa (Sofosbuvir/Velpatasvir) For The Treatment Of Chronic Hepatitis C In Patients Co-Infected With HIV. Gilead, 1 Aug 2017.https://www.gilead.com/news-and-press/press-room/press-releases/2017/8/us-fda-approves-expanded-labeling-for-epclusa-sofosbuvirvelpatasvir-for-the-treatment-of-chronic-hepatitis-c-in-patients-coinfected-with-hiv
- U.S. Food and drug administration approves New formulation of epclusa, expanding pediatric indication to treat children ages 3 and older with chronic hepatitis C. Gilead, 10 Jun 2021. https://www.gilead.com/news-and-press/press-room/press-releases/2021/6/us-food-and-drug-administration-approves-new-formulation-of-epclusa-expanding-pediatric-indication-to-treat-children-ages-3-and-older-with-chronic
- Greenaway E, Haines A, Ling SC, et al. Treatment of chronic hepatitis C in Young children Reduces adverse outcomes and is cost-effective compared with deferring treatment to adulthood. J Pediatr. 2021;230:38–45.e2. doi: 10.1016/j.jpeds.2020.08.088
- Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and Voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153(1):113–122. doi: 10.1053/j.gastro.2017.03.047
- Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–1888. doi: 10.1056/NEJMoa1402355
- Ogbuagu O, Hao R, Virata M, et al. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. F1000Res. 2017 [cited 2017 May 3];6:620. doi: 10.12688/f1000research.11397.1
- Serranti D, Dodi I, Nicastro E, et al. Shortened 8-week course of sofosbuvir/ledipasvir therapy in adolescents with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr. 2019;69(5):595–598. doi: 10.1097/MPG.0000000000002449
- Thomas DL, Owen A, Kiser JJ. Prospects for long-acting treatments for hepatitis C. Clin Infect Dis. 2022;75(Suppl 4):S525–S529. doi: 10.1093/cid/ciac715
- Kushner T, Cohen J, Tien PC, et al. Evaluating Women's preferences for hepatitis C treatment during pregnancy. Hepatol Commun. 2018Oct 1;2(11):1306–1310. doi: 10.1002/hep4.1264. PMID: 30411077; PMCID: PMC6211328.
- Mogalian E, Stamm LM, Osinusi A, et al. Drug-drug interaction studies between hepatitis C virus antivirals sofosbuvir/velpatasvir and boosted and unboosted human immunodeficiency virus antiretroviral regimens in healthy volunteers. Clin Infect Dis. 2018;67(6):934–940. doi: 10.1093/cid/ciy201